Stada ‘Continuously Evaluating’ OTC Deals As Sales Grow Double Digits
Executive Summary
Stada tells HBW Insight it remains on the lookout for deals despite only last month closing the acquisition of a basket of OTC brands from GSK. The German firm revealed its plans as it reported a double-digit rise in both sales and earnings at its Branded Products business for the opening six months of 2019.
You may also be interested in...
Stada’s Acquisition Spree Continues With Deal For Ukrainian Probiotics Player
Germany's Stada will gain a range of probiotics and other OTC brands through the acquisition of Ukraine's Biopharma. The deal is Stada's third in the space of just one month.
Winter Is Coming: CHC Firms Battle It Out In Germany’s Crowded Cough And Cold Market
Consumer healthcare firms large and small will fight it out this winter for dominance in Germany's OTC cough and cold market.
Stada Reveals Skin-Care Ambitions With Acquisition Of GSK Brands
Stada has snapped up a basket of OTC skin-care brands from GSK, with CEO Peter Goldschmidt telling HBW Insight that the category is a "key focus" for the Germany-based firm.